Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1973 May;27(5):406–408. doi: 10.1038/bjc.1973.49

The emergence of drug resistance in tumours: a characteristic which may be exploited therapeutically.

M H Tattersall
PMCID: PMC2008802  PMID: 4576563

Full text

PDF
406

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bruce W. R., Meeker B. E., Valeriote F. A. Comparison of the sensitivity of normal hematopoietic and transplanted lymphoma colony-forming cells to chemotherapeutic agents administered in vivo. J Natl Cancer Inst. 1966 Aug;37(2):233–245. [PubMed] [Google Scholar]
  2. Capizzi R. L., DeConti R. C., Marsh J. C., Bertino J. R. Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin "rescue". Cancer Res. 1970 Jun;30(6):1782–1788. [PubMed] [Google Scholar]
  3. Djerassi I., Rominger C. J., Kim J. S., Turchi J., Suvansri U., Hughes D. Phase I study of high doses of methotrexate with citrovorum factor in patients with lung cancer. Cancer. 1972 Jul;30(1):22–30. doi: 10.1002/1097-0142(197207)30:1<22::aid-cncr2820300105>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  4. FRIEDKIN M., CRAWFORD E., HUMPHREYS S. R., GOLDIN A. The association of increased dihydrofolate reductase with amethopterin resistance in mouse leukemia. Cancer Res. 1962 Jun;22:600–606. [PubMed] [Google Scholar]
  5. Fass R. J., Perkins R. L. 5-fluorocytosine in the treatment of cryptococcal and candida mycoses. Ann Intern Med. 1971 Apr;74(4):535–539. doi: 10.7326/0003-4819-74-4-535. [DOI] [PubMed] [Google Scholar]
  6. HEIDELBERGER C., CHAUDHURI N. K., DANNEBERG P., MOOREN D., GRIESBACH L., DUSCHINSKY R., SCHNITZER R. J., PLEVEN E., SCHEINER J. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957 Mar 30;179(4561):663–666. doi: 10.1038/179663a0. [DOI] [PubMed] [Google Scholar]
  7. Koechlin B. A., Rubio F., Palmer S., Gabriel T., Duschinsky R. The metabolism of 5-fluorocytosine-2-14-C and of cytosine-14-C in the rat and the disposition of 5-fluorocytosine-2-14-C in man. Biochem Pharmacol. 1966 Apr;15(4):435–446. doi: 10.1016/0006-2952(66)90254-1. [DOI] [PubMed] [Google Scholar]
  8. Mishra L. C., Mead J. A. Further evaluation of the antitumor activity of homofolate and its reduced derivatives against methotrexate-insensitive tumors. Chemotherapy. 1972;17(4):283–292. doi: 10.1159/000220859. [DOI] [PubMed] [Google Scholar]
  9. OSBORN M. J., FREEMAN M., HUENNEKENS F. M. Inhibition of dihydrofolic reductase by aminopterin and amethopterin. Proc Soc Exp Biol Med. 1958 Feb;97(2):429–431. doi: 10.3181/00379727-97-23764. [DOI] [PubMed] [Google Scholar]
  10. Steuart C. D., Burke P. J. Cytidine deaminase and the development of resistance to arabinosyl cytosine. Nat New Biol. 1971 Sep 22;233(38):109–110. doi: 10.1038/newbio233109a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES